109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
含或不含安罗替尼的放化疗治疗食管鳞状细胞癌术后淋巴结复发：一项真实世界观察性研究
Authors Zhu J, Tong YS , Zhu WG, Wang WW, Ji FZ, Zhou XL
Received 2 June 2025
Accepted for publication 13 September 2025
Published 15 October 2025 Volume 2025:19 Pages 9331—9342
DOI https://doi.org/10.2147/DDDT.S544203
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Anastasios Lymperopoulos
Jing Zhu,1,* Yu-Suo Tong,2,* Wei-Guo Zhu,2 Wan-Wei Wang,2 Fu-Zhi Ji,2 Xi-Lei Zhou2
1Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China; 2Department of Radiation Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xi-Lei Zhou, Department of Radiation Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China, Email zhouxilei1226@163.com
Purpose: Anlotinib, a tyrosine kinase inhibitor, has shown encouraging anti-tumor activity in esophageal squamous cell carcinoma (ESCC). This study present real-world data on the efficacy and safety of chemoradiotherapy (CRT) plus anlotinib versus CRT alone in patients with lymph node recurrence of ESCC after radical resection.
Patients and Methods: Patients with lymph node recurrence of ESCC who received CRT with or without anlotinib between January 2017 and December 2019 were retrospectively analyzed. Treatment response, overall survival (OS), progression free survival (PFS) and treatment-related toxicities were compared between groups. Propensity score matching (PSM) analysis was used to balance baseline covariates.
Results: A total of 291 ESCC patients with lymph node recurrence received CRT plus anlotinib (n = 76) or CRT alone (n = 215). After PSM, 68 well-balanced patients in each group were included. The partial response rate (58.8% vs 41.2%, p = 0.04) and objective response rate (86.7% vs 61.8%, p = 0.001) were significantly higher in the CRT plus anlotinib group than in the CRT group. Patients in the CRT plus anlotinib group had significantly longer OS (3-year OS, 42.7% vs 23.5%, p = 0.008) and PFS (12-month PFS, 47.1% vs 32.4%, p = 0.026) than those in the CRT group. Multivariate survival analysis revealed that the treatment group (p = 0.007) was an independent predictor of OS. No significant differences were observed in grade 3– 4 treatment-related adverse events between the two groups (39.5% vs 30.7%, p = 0.162).
Conclusion: Compared with CRT alone, the addition of anlotinib to CRT was safe and provided survival benefits in ESCC patients with lymph node recurrence after radical resection.
Keywords: esophageal squamous cell carcinoma, lymph node recurrence, chemoradiotherapy, anlotinib, survival
1Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China; 2Department of Radiation Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xi-Lei Zhou, Department of Radiation Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China, Email zhouxilei1226@163.com
Purpose: Anlotinib, a tyrosine kinase inhibitor, has shown encouraging anti-tumor activity in esophageal squamous cell carcinoma (ESCC). This study present real-world data on the efficacy and safety of chemoradiotherapy (CRT) plus anlotinib versus CRT alone in patients with lymph node recurrence of ESCC after radical resection.
Patients and Methods: Patients with lymph node recurrence of ESCC who received CRT with or without anlotinib between January 2017 and December 2019 were retrospectively analyzed. Treatment response, overall survival (OS), progression free survival (PFS) and treatment-related toxicities were compared between groups. Propensity score matching (PSM) analysis was used to balance baseline covariates.
Results: A total of 291 ESCC patients with lymph node recurrence received CRT plus anlotinib (n = 76) or CRT alone (n = 215). After PSM, 68 well-balanced patients in each group were included. The partial response rate (58.8% vs 41.2%, p = 0.04) and objective response rate (86.7% vs 61.8%, p = 0.001) were significantly higher in the CRT plus anlotinib group than in the CRT group. Patients in the CRT plus anlotinib group had significantly longer OS (3-year OS, 42.7% vs 23.5%, p = 0.008) and PFS (12-month PFS, 47.1% vs 32.4%, p = 0.026) than those in the CRT group. Multivariate survival analysis revealed that the treatment group (p = 0.007) was an independent predictor of OS. No significant differences were observed in grade 3– 4 treatment-related adverse events between the two groups (39.5% vs 30.7%, p = 0.162).
Conclusion: Compared with CRT alone, the addition of anlotinib to CRT was safe and provided survival benefits in ESCC patients with lymph node recurrence after radical resection.
Keywords: esophageal squamous cell carcinoma, lymph node recurrence, chemoradiotherapy, anlotinib, survival